Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Gram-Negative Infections | Current Treatment: Physician Insights | US | 2018

Login to access report north_east
Contact sales account_box

MARKET OUTLOOK

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with these agents, making it difficult for branded products like Merck & Co.’s Zerbaxa, Allergan’s Avycaz, and Melinta’s Vabomere to gain uptake in earlier lines of therapy. However, rising antimicrobial resistance rates have created the need for safer products to effectively treat drug-resistant GNIs, and, as our primary market research shows, activity against key drug-resistant pathogens is an important driver of brand use. Furthermore, hospital-based infectious disease (ID) specialists report shifts in their approach to treating GNIs in response to the climbing rates of drug resistance.

QUESTIONS ANSWERED

  • What are the most prescribed first-, second-, and third-line therapies for inpatients with a urinary tract infection, nosocomial pneumonia, or complicated intra-abdominal infection?
  • How are physicians approaching the treatment of infections caused by drug-resistant pathogens?
  • Which clinical and nonclinical factors drive, and prevent, the prescribing of brand agents such as Zerbaxa, Avycaz, and Tygacil? What are the most common therapies that patients receive prior to being prescribed Zerbaxa,  Avycaz or Tygacil?
  • What will be the impact of the recent approval of Vabomere? What will drive its use and in which populations will it be used? Which current agents will be most affected by its prescribing?

PRODUCT DESCRIPTION

Provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics to more effectively increase or defend your market position.

Markets covered: United States

Primary research: Survey of 104 hospital-based ID specialists in the United States

Key drugs: Avycaz, Zerbaxa, Vabomere, Invanz, Teflaro, Tygacil, Minocin, and other key GNI generic drugs

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
north_east
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
north_east
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
north_east
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
north_east
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east